Targan Raises $35M in Series C Financing

Targan (formerly Applied LifeSciences & Systems (ALSS), a Morrisville, NC-based Biotechnology Systems company innovating animal protein production industries worldwide by bringing individualized care technologies to the market, raised $35M in Series C financing.

The round was led by Mountain Group Partners and NovaQuest Capital Management with participation from existing investors Merck Animal Health and Oval Park Capital.

The company intends to use the funds to to accelerate the commercialization of its automated and individualized poultry vaccination and gender identification systems.

Led by Ramin Karimpour, founder and CEO, Targan aims to bring individualized care technologies to the Poultry, Aquaculture, and Swine industries.

The company integrates its proprietary technologies consisting of high-speed imaging, feature recognition, artificial intelligence, robotics, and microfluidics in a system currently developed for the commercial poultry industry. This system can individually and accurately vaccinate up to 100,000 chicks per hour against diseases such as coccidiosis, infectious bronchitis, and Newcastle disease.  In addition, Targan has developed a fully automated system that can determine the gender of individual chicks to allow separate sex rearing by poultry producers.